Terms: = Pancreatic cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
327 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With pancreatic cancer Treated With Perioperative Adjuvant Chemotherapy.
Kawahara S; Aoyama T; Murakawa M; Kanemoto R; Takahashi D; Kamioka Y; Hashimoto I; Maezawa Y; Kobayashi S; Ueno M; Yamamoto N; Oshima T; Yukawa N; Rino Y; Saito A; Morinaga S
Anticancer Res; 2024 Apr; 44(4):1711-1718. PubMed ID: 38537971
[TBL] [Abstract] [Full Text] [Related]
3. Thyroid poorly differentiated carcinoma metastatic to pancreas diagnosed by fine-needle aspiration and demonstrating a novel braf fusion.
Ahmadian SS; Jones D; Wakely P; Lott Limbach AA
Cytopathology; 2024 May; 35(3):408-411. PubMed ID: 38361348
[TBL] [Abstract] [Full Text] [Related]
4. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
[TBL] [Abstract] [Full Text] [Related]
5. Near complete remission of an inoperable pancreatic acinar cell carcinoma after braf-/MEK-inhibitor treatment-A case report and review of the literature.
von Fritsch L; von Bubnoff N; Weber K; Kirfel J; Schreiber C; Keck T; Wellner U
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23222. PubMed ID: 38340027
[TBL] [Abstract] [Full Text] [Related]
6. Ex vivo modeling of acquired drug resistance in braf - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.
Steiner S; Pliego-Mendieta A; Haberecker M; Hussung S; Kollár A; Fritsch R; Arnold F; Lenggenhager D; Planas-Paz L; Pauli C
Cancer Lett; 2024 Mar; 584():216650. PubMed ID: 38246222
[TBL] [Abstract] [Full Text] [Related]
7. RNF43 Inactivation Enhances the b-raf/MEK Signaling and Creates a Combinatory Therapeutic Target in cancer Cells.
Hsu SH; Tsai YL; Wang YT; Shen CH; Hung YH; Chen LT; Hung WC
Adv Sci (Weinh); 2024 Mar; 11(12):e2304820. PubMed ID: 38225722
[TBL] [Abstract] [Full Text] [Related]
8. cancer mortality and morbidity among patients with schizophrenia: A hospital-based cohort study, 1992-2020.
Drevinskaite M; Kaceniene A; Patasius A; Stukas R; Germanavicius A; Miseikyte E; Urbonas V; Smailyte G
Acta Psychiatr Scand; 2024 Mar; 149(3):234-243. PubMed ID: 38173088
[TBL] [Abstract] [Full Text] [Related]
9. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
10. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
11. Mucinous cystadenocarcinoma of the breast harbours TRPS1 expressions and PIK3CA alterations.
Chen WY; Hu YH; Tsai YH; Hang JF; Tan PH; Chen CJ
Histopathology; 2024 Feb; 84(3):550-555. PubMed ID: 37983855
[TBL] [Abstract] [Full Text] [Related]
12. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and braf-mutant colorectal cancer cells.
Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
[TBL] [Abstract] [Full Text] [Related]
13. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset pancreatic cancer.
Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
[TBL] [Abstract] [Full Text] [Related]
14. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation.
Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T
Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686
[TBL] [Abstract] [Full Text] [Related]
15. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
Jiagge E; Jin DX; Newberg JY; Perea-Chamblee T; Pekala KR; Fong C; Waters M; Ma D; Dei-Adomakoh Y; Erb G; Arora KS; Maund SL; Njiraini N; Ntekim A; Kim S; Bai X; Thomas M; van Eeden R; Hegde P; Jee J; Chakravarty D; Schultz N; Berger MF; Frampton GM; Sokol ES; Carrot-Zhang J
Cancer Cell; 2023 Nov; 41(11):1963-1971.e3. PubMed ID: 37890492
[TBL] [Abstract] [Full Text] [Related]
16. Gene Rearrangement and Expression of PRKACA and PRKACB Govern Morphobiology of Pancreatobiliary Oncocytic Neoplasms.
Itoh T; Omori Y; Seino M; Hirose K; Date F; Ono Y; Mizukami Y; Aoki S; Ishida M; Mizuma M; Morikawa T; Higuchi R; Honda G; Okamura Y; Kinoshita K; Unno M; Furukawa T
Mod Pathol; 2024 Jan; 37(1):100358. PubMed ID: 37871652
[TBL] [Abstract] [Full Text] [Related]
17. The EMT factor ZEB1 paradoxically inhibits EMT in braf-mutant carcinomas.
Sánchez-Tilló E; Pedrosa L; Vila I; Chen Y; Győrffy B; Sánchez-Moral L; Siles L; Lozano JJ; Esteve-Codina A; Darling DS; Cuatrecasas M; Castells A; Maurel J; Postigo A
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37870961
[TBL] [Abstract] [Full Text] [Related]
18. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
19.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract] [Full Text] [Related]
20. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable braf V600E mutant colorectal oligometastases.
Kobayashi S; Bando H; Taketomi A; Takamoto T; Shinozaki E; Shiozawa M; Hara H; Yamazaki K; Komori K; Matsuhashi N; Kato T; Kagawa Y; Yokota M; Oki E; Komine K; Takahashi S; Wakabayashi M; Yoshino T
BMC Cancer; 2023 Aug; 23(1):779. PubMed ID: 37605122
[TBL] [Abstract] [Full Text] [Related]
[Next]
